[Clinical-economic substantiation of immunocorrection therapy of Epstein-Barr viral mononucleosis in children].
Results are presented for a group of 299 patients aged 1-14 with primary Epstein--Barr viral infection. Features of the process of a infectious mononucleosis are revealed for various kinds of immunocorrection therapy. A clinical-economic estimation of the immunocorrection therapy in children with primary Epstein-Barr viral infection has been performed.